Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
Tesamorelin
Batch #
P250225-LC1120088
Formula
C221H366N72O67S
Mol Wt
5135.89 g/mol
CAS
218949-48-5
Latest
ISO 17025
8× Testing
99.23%
Purity
VariantTesamorelin
COA ##11578
Labeled5mg
Validation KeyAXISBIOTECH
Tested12/15/25
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.23%
✓
Net Peptide Content - 5mg
✓
Identity (HPLC) - Tesamorelin
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - 99.94%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Effects of growth hormone-releasing factor on abdominal fat in HIV-infected patients with fat accumulation
02
Tesamorelin reduces visceral fat in HIV-infected patients: results from two Phase 3 clinical trials
03
EGRIFTA (tesamorelin) — FDA Approval for HIV-associated lipodystrophy
04
Tesamorelin effects on non-alcoholic fatty liver disease in HIV-infected patients
05
Effects of tesamorelin on quality of life in HIV-infected patients with excess abdominal fat
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
